Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466124 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL3486221 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29434320 | 1.00 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29388140 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29534023 | 0.94 | GHSR (0.55) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL14509563 | 0.91 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL31404052 | 0.90 | GHSR (0.68) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL21185972 | 0.90 | IL23R (0.65) | KISS1RIL23R | |
| SCHEMBL16358972 | 0.88 | GHSR (0.61) | GHSRUTS2R | |
| SCHEMBL30053610 | 0.88 | GHSR (0.71) | GHSRNPY1RNPY2RNPY4RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117427214-A | Self-healing hydrogel and preparation method thereof | 中国人民解放军陆军特色医学中心 | 2024-01-23 | — | — | CN | claimed |
| CN-114099692-B | Antibacterial peptide-cell membrane compound, preparation method and application | 西南大学 | 2023-06-09 | — | — | CN | claimed |
| CN-115873072-A | Turtle meat source ACE inhibitory peptide and screening method thereof | 广西中医药大学 | 2023-03-31 | — | — | CN | claimed |
| EP-4736869-A2 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY PROTEIN NITRATION COMPRISING PEPTIDE WITH TERMINAL TYROSINE AS EFFECTIVE COMPONENT | Industry-Academic Cooperation Foundation Gyeongsang National University (KR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736868-A2 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY PROTEIN NITRATION COMPRISING PEPTIDE WITH TERMINAL TYROSINE AS EFFECTIVE COMPONENT | Industry-Academic Cooperation Foundation Gyeongsang National University (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260021025-A1 | STRUCTURALLY DIVERSE, STABLE, AND RADIATION-PROTECTIVE PARTICLE MATRIX SUNSCREEN AND COSMETIC COMPOSITIONS AND RELATED METHODS | LCS ADVANCED SOLUTIONS LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | RESOTHER PHARMA AS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-12453681-B2 | Structurally diverse, stable, and radiation-protective particle matrix sunscreen and cosmetic compositions and related methods | LCS Advanced Solutions, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| CN-115873072-B | ACE (angiotensin converting enzyme) inhibitory peptide derived from turtle meat and screening method thereof | 广西中医药大学 | 2025-09-19 | — | — | CN | disclosed |
| US-20250277789-A1 | METHOD OF IMPROVING PREDICTION ACCURACY AND REDUCING FALSE NEGATIVE RATE OF SEVERE DENGUE PREDICTION IN SUBJECT | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2025-09-04 | — | — | US | disclosed |
| US-20250205164-A1 | FPR2 AGONIST CONTAINING OUTER MEMBRANE VESICLES DERIVED FROM LACTIC ACID BACTERIUM | ASAHI GROUP HOLDINGS, LTD. (JP) | 2025-06-26 | — | — | US | disclosed |
| WO-2022177418-A1 | UMAMI-ENHANCING COMPOSITION CONTAINING TYROSINE-AMINO ACID PEPTIDE, AND USES THEREOF | 경상국립대학교산학협력단 | 2022-08-25 | — | — | WO | disclosed |
| US-20220268774-A1 | METHOD OF ELEVATING PREDICTION ACCURACY OF GROUPING SUBJECTS WITH SEVERE DENGUE INFECTION | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2022-08-25 | — | — | US | disclosed |
| US-11384144-B2 | T cell receptor-like antibodies specific for a PRAME peptide | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-07-12 | — | — | US | disclosed |
| CN-107921127-B | T cell receptor-like antibodies specific for PRAME peptides | 纪念斯隆-凯特琳癌症中心 | 2022-04-08 | — | — | CN | disclosed |
| US-11274126-B2 | pH-sensitive cyclic peptides | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220040255-A1 | CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
| US-20100035822-A1 | PROLINE-RICH PEPTIDES, PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE PEPTIDES AND METHOD OF TREATMENT | PEP FARMA CONSULTORIA E DESENVOLVIMENTO FARMACEUTI (BR) | 2010-02-11 | — | — | US | disclosed |
| EP-1979373-A2 | PROLINE-RICH PEPTIDES, PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE PEPTIDES AND METHOD OF TREATMENT | PEP Farma Consultoria e Desenvolvimento Farmacêutico Ltda (BR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007079558-A2 | PROLINE-RICH PEPTIDES, PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE PEPTIDES AND METHOD OF TREATMENT | PEP FARMA CONSULTORIA E DESENVOLVIMENTO FARMACÊUTICO LTDA (BR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274126-B2 | pH-sensitive cyclic peptides | VIP, PHLPP1, PHLPP2 | GHSR 1533/4885NPY1R 1360/4885NPY2R 1654/4885 |
| US-20250388632-A1 | ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES | ANXA11, ANXA1, ANXA4 | GHSR 2471/4885NPY1R 253/4885NPY2R 669/4885 |
| US-20260021025-A1 | STRUCTURALLY DIVERSE, STABLE, AND RADIATION-PROTECTIVE PARTICLE MATRIX SUNSCREEN AND COSMETIC COMPOSITIONS AND RELATED METHODS | CYP24A1, TSLP, BRCA1 | GHSR 3632/4885NPY1R 4213/4885NPY2R 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.